港股异动 | 科济药业-B(02171)涨超6% 恺力美®研究结果即将于2026年ESMO年会进行壁报展示

智通财经07-15

智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨5.94%，报16.42港元，成交额3262.85万港元。消息面上，7月15日，据科济药业官微消息，公司宣布，恺力美®(舒瑞基奥仑赛注射液，产品编号：CT041，一种靶向Claudin18.2的自体CAR-T细胞治疗候选产品)在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验(CT041-CG4010...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2651843550?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651843550","market":"hk","top_or_hot":-1,"title":"港股异动 | 科济药业-B(02171)涨超6% 恺力美®研究结果即将于2026年ESMO年会进行壁报展示","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨5.94%，报16.42港元，成交额3262.85万港元。消息面上，7月15日，据科济药业官微消息，公司宣布，恺力美®(舒瑞基奥仑赛注射液，产品编号：CT041，一种靶向Claudin18.2的自体CAR-T细胞治疗候选产品)在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验(CT041-CG4010...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1467670.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科济药业-B(02171)涨超6% 恺力美®研究结果即将于2026年ESMO年会进行壁报展示</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科济药业-B(02171)涨超6% 恺力美®研究结果即将于2026年ESMO年会进行壁报展示\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 10:49 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1467670.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨5.94%，报16.42港元，成交额3262.85万港元。消息面上，7月15日，据科济药业官微消息，公司宣布，恺力美®(舒瑞基奥仑赛注射液，产品编号：CT041，一种靶向Claudin18.2的自体CAR-T细胞治疗候选产品)在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验(CT041-CG4010...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1467670.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1467670.html","article_id":"2651843550","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651843550","pubTimestamp":1784083754,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，科济药业-B涨超6%，截至发稿，涨5.94%，报16.42港元，成交额3262.85万港元。消息面上，7月15日，据科济药业官微消息，公司宣布，恺力美在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验初步积极结果已被2026年欧洲肿瘤内科学会年会接受进行壁报展示。科济药业表示，截至7月15日，CT041-CG4010自2025年5月启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1587":"次新股","02171":"科济药业-B","BK1574":"生物医药B类股","KCAI":"KraneShares China Alpha Index ETF","BK1585":"昨日强势股"},"translate_title":"Hong Kong stock changes | Keji Pharmaceutical-B (02171) rose more than 6% Kailimei ® The findings will soon be presented in a wall poster at the 2026 ESMO Annual Meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"KCAI":1.5,"02171":1.5},"content_text":"智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨5.94%，报16.42港元，成交额3262.85万港元。消息面上，7月15日，据科济药业官微消息，公司宣布，恺力美®(舒瑞基奥仑赛注射液，产品编号：CT041，一种靶向Claudin18.2的自体CAR-T细胞治疗候选产品)在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验(CT041-CG4010, NCT06857786)初步积极结果已被2026年欧洲肿瘤内科学会(ESMO)年会接受进行壁报展示。摘要将于2026年10月19日(星期一)欧洲中部夏令时间(CEST)00:05于ESMO官网公布。科济药业表示，截至7月15日，CT041-CG4010自2025年5月启动入组以来，所有接受恺力美®治疗的参与者均未发生胃癌术后复发或转移。恺力美®是一款全球同类首创靶向Claudin18.2蛋白的自体CAR-T细胞治疗产品，用于治疗Claudin18.2阳性实体瘤。恺力美®于2026年6月获国家药品监督管理局批准上市，用于治疗Claudin18.2阳性、人表皮生长因子受体2(HER2)阴性，至少二线治疗失败的晚期胃/食管胃结合部腺癌(G/GEJA)，成为全球首个批准上市实体瘤CAR-T细胞治疗品种。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651843550","isCrawlerRequest":true}